Previous Article | Next Article 
Journal of Virology, June 1999, p. 4651-4661, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
B Cells Regulate Murine Gammaherpesvirus 68 Latency
Karen E.
Weck,
Susanne S.
Kim,
Herbert W.
Virgin IV,* and
Samuel H.
Speck*
Center for Immunology and Departments of
Pathology and Molecular Microbiology, Washington University School
of Medicine, St. Louis, Missouri 63110
Received 2 November 1998/Accepted 23 February 1999
 |
ABSTRACT |
The dynamics of the establishment of, and reactivation from,
gammaherpesviruses latency has not been quantitatively analyzed in the
natural host. Gammaherpesvirus 68 (
HV68) is a murine
gammaherpesvirus genetically related to primate gammaherpesviruses that
establishes a latent infection in infected mice. We used limiting
dilution reactivation (frequency of cells reactivating
HV68 in
vitro) and limiting dilution PCR (frequency of cells carrying
HV68
genome) assays to compare
HV68 latency in normal (C57BL/6) and
B-cell-deficient (MuMT) mice. After intraperitoneal (i.p.) inoculation,
latent
HV68 was detected in the spleen, bone marrow, and peritoneal cells. Both B-cell-deficient and C57BL/6 mice established latent infection in peritoneal cells after either i.p. or intranasal (i.n.)
inoculation. In contrast, establishment of splenic latency was less
efficient in B-cell-deficient than in C57BL/6 mice after i.n.
inoculation. Analysis of reactivation efficiency (reactivation frequency compared to frequency of cells carrying
HV68 genome) revealed that (i) regardless of route or mouse strain, splenic cells
reactivated
HV68 less efficiently than peritoneal cells, (ii) the
frequency of cells carrying
HV68 genome was generally comparable
over the course of infection between C57BL/6 and B-cell-deficient mice,
(iii) between 28 and 250 days after infection, cells from B-cell-deficient mice reactivated
HV68 10- to 100-fold more
efficiently than cells from C57BL/6 mice, (iv) at 7 weeks
postinfection, B-cell-deficient mice had more genome-positive
peritoneal cells than C57BL/6 mice, and (v) mixing cells (ratio of 3 to
1) that reactivated inefficiently with cells that reactivated
efficiently did not significantly decrease reactivation efficiency.
Consistent with a failure to normally regulate chronic
HV68
infection, the majority of infected B-cell-deficient mice died between
100 and 200 days postinfection. We conclude that (i) B cells are not
required for establishment of
HV68 latency, (ii) there are
organ-specific differences in the efficiency of
HV68 reactivation,
(iii) B cells play a crucial role in regulating reactivation of
HV68
from latency, and (iv) B cells are important for controlling chronic
HV68 infection.
 |
INTRODUCTION |
Murine gammaherpesvirus 68 (
HV68)
was isolated from a vole, and it infects outbred and inbred mice. The
genomic sequence of
HV68 is available and confirms its close
relationship with other gammaherpesviruses (22), including
Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (also called
human herpesvirus 8).
HV68 can acutely infect multiple organs of
mice, including the spleen, liver, lung, kidney, adrenal glands, heart,
and thymus (13, 18). Infection has been associated with
splenomegaly, pneumonitis, and a fatal arteritis in mice lacking
responsiveness to gamma interferon (18, 20, 24, 25). An
association of
HV68 with the development of lymphomas has been
reported (17). It has been shown that
HV68 can establish
a latent infection in the spleen (18, 19, 24), and B cells
have been implicated as the predominant latent cell type in
hematopoietic cells in vivo (19). Because of its genomic
structure, association with lymphomas, and evidence that it establishes
a latent infection in B lymphocytes,
HV68 has been suggested as a
murine model for EBV and Kaposi's sarcoma herpesvirus (10, 11,
15, 19, 22).
To further examine the role of B cells in
HV68 infection and
latency, we analyzed
HV68 infection of B-cell-deficient mice. These
mice are deficient in mature B cells by virtue of a homozygous mutation
in the transmembrane exon of the µ heavy-chain gene (9). Previously, we have shown that
HV68 can establish latency in B-cell-deficient mice (24), thus demonstrating that B
lymphocytes are not required for establishment of latency by
HV68.
We extend these observations here, demonstrating a role for B cells in
regulating
HV68 latency, as measured by a quantitative limiting
dilution reactivation assay. Further studies, comparing the
relationship between viral reactivation and the frequency of
HV68-genome positive cells in vivo, provide evidence for
organ-specific differences in
HV68 latency and for a critical role
for B cells in regulating
HV68 reactivation from latency.
 |
MATERIALS AND METHODS |
Mice, infections, and organ harvests.
B-cell-deficient mice
backcrossed onto a C57BL/6 background (C57BL/6J-Igh-6tm1Cgn
mice) were purchased from The Jackson Laboratory (Bar Harbor, Maine).
Mice were then bred and maintained at Washington University, St. Louis,
Mo., in accordance with all university and federal guidelines. C57BL/6
mice were purchased from The Jackson Laboratory. Mice were infected
with 106 PFU of
HV68 in Dulbecco modified Eagle medium
(DMEM)-10% fetal calf serum either in a 1-ml volume for
intraperitoneal (i.p.) inoculation or 10-µl volume for intranasal
(i.n.) inoculation.
HV68 WUMS strain (ATCC VR1465) was used for all
infections. The viral stock was passaged once on NIH 3T12 cells for
amplification. Three separate first-round passages of the ATCC VR1465
stock were used in these studies. At various times postinfection, mice
were sacrificed by cervical dislocation after metofane anesthesia, and
various organs were harvested and analyzed for latent virus. All organs
were harvested in DMEM-10% fetal calf serum. Resident peritoneal
exudate cells (PECs) were harvested by peritoneal lavage with 10 ml of
medium (6). Spleens and thymuses were disrupted in a tissue
homogenizer, using a protocol that preserves cell viability, and
filtered over Nitex to remove splenic stroma (1). Bone
marrow cells were harvested from the femurs and tibias of mice, by
flushing with several milliliters of medium (5, 12). Erythrocytes were lysed with ammonium chloride, and cells were washed
and resuspended in DMEM-10% fetal calf serum.
Limiting dilution ex vivo reactivation assay to detect latent
virus.
MEF (mouse embryonic fibroblast) cells were obtained from
BALB/c mice and maintained as previously described (24).
Limiting dilution analysis to detect reactivation from latency was
performed as previously described (24). Briefly, serial
twofold dilutions of test cells harvested from mice were plated onto
indicator MEF cells in 96-well tissue culture plates. The wells were
scored microscopically for viral cytopathic effect (CPE) after 3 weeks. A maximum of 100,000 cells was plated per well, as greater numbers of
cells were toxic to the MEF monolayer. To measure the presence of
preformed infectious virus in the test cell populations, the cells were
killed prior to plating by mechanical disruption in 1/3× DMEM in the
presence of 0.5-mm-diameter silica beads in a Mini-Beadbeater-8
(Biospec Products, Bartlesville, Okla.). Controls for the specificity
and sensitivity of this assay are presented in Results. No difference
in reactivation from latency was observed for MEF cells derived from
BALB/c or from C57BL/6 mice.
Detection of
HV68 DNA by nested PCR.
Nested PCR to detect
the ORF (open reading frame) 50 gene of
HV68 was shown to have a
sensitivity of one copy of
HV68 DNA. The sequences of the outer PCR
primers used were 5'-AACTGGAACTCTTCTGTGGC-3' and
5'-GGCCGCAGACATTTAATGAC-3', which amplify a 586-bp product. The sequences of the inner PCR primers used were
5'-CCCCAATGGTTCATAAGTGG-3' and
5'-ATCAGCACGCCATCAACATC-3', which amplify a 382-bp product. Primers were synthesized by GIBCO BRL. Each PCR mixture contained 50 mM
KCl, 10 mM Tris-HCl (pH 8.5), 0.1% Triton X-100, 1.5 mM MgCl2, 0.2 mM nucleotides, 1 ng of each primer per µl,
and 1 U of Taq polymerase (Promega). PCRs were performed on
a Perkin-Elmer 9600 GENEAMP thermocycler. The initial round of PCR was
performed in a 20-µl total volume with 45 cycles of 94°C for
30 s, 60°C for 30 s, and 72°C for 30 s, followed by
extension at 72°C for 5 min. The conditions for the second round of
PCR were identical except that the reaction mixture was amplified for
25 cycles. For the second round, 1 µl of the first-round PCR was
amplified in a total volume of 10 µl. Second-round PCR products were
visualized by electrophoresis on a 2% agarose gel stained with
ethidium bromide. Plasmid pBamHI N containing ORF 50 of
HV68, kindly
provided by Stacey Efstathiou (4), was used to determine the
sensitivity of the nested PCR for detection of
HV68 DNA. pBamHI N
was quantitated spectrophotometrically and diluted in mouse liver DNA
or tRNA (0.5 mg/ml) in Tris-EDTA. One microgram of total nucleic acid from serial 10-fold dilutions of pBamHI N in mouse liver DNA or tRNA
was analyzed by nested PCR in a series of control PCRs.
Determination of the frequency of latently infected cells
harboring the
HV68 genome.
To determine the frequency of cells
carrying the
HV68 genome in spleen and PECs from latently infected
mice, nested PCR (single-copy sensitivity) was performed on serial
dilutions of cells, using a previously published method (12)
or an adaptation of the previously published method described here.
Briefly, test cells were diluted in an isotonic medium (150 mM KCl, 10 mM Tris-HCl [pH 7.5], 1.5 mM MgCl2) in a background of
uninfected MEF cells. To keep the total cell number constant for each
PCR, serial fourfold dilutions of cells ranging from 10,000 test cells
to 2.5 test cells per PCR, with a total of 10,000 cells (MEF plus test
cells) per PCR, were made. Twelve to 24 PCRs were analyzed per cell
concentration. Five-microliter cell dilutions were added to PCR tubes
containing 5 µl of lysis buffer (10 mM Tris-HCl [pH 8.5], 1.5 mM
MgCl2, 1% Nonidet P-40, 1% Tween 20, 0.2 mg of proteinase
K per ml) and were lysed overnight at 56°C. Proteinase K was
inactivated at 95°C for 15 min, and 10 µl of adjusted PCR cocktail
(25 mM KCl, 10 mM Tris-HCl [pH 9.0], 0.5% Triton X-100, 1.5 mM
MgCl2, 2× deoxynucleoside triphosphates, primers,
Taq polymerase) was added directly to each cell lysate, so
that final PCR conditions were as described above. Nested PCR was
performed as described above. The dilutional nested PCR method was
shown to have a sensitivity of one copy of
HV68 DNA in a background
of 10,000 cells, by adding dilutions of plasmid pBamHI N to 10,000 uninfected MEF cells prior to cell lysis. These controls for one-copy
sensitivity, as well as negative controls of MEF cells alone or water
alone, were included for each set of PCRs performed. In addition,
one-copy sensitivity for
HV68 DNA was observed when 106
copies of pBamHI N plasmid DNA were added to naive spleen cells and
subsequently diluted, demonstrating that target DNA was not destroyed
during the lysis procedure.
 |
RESULTS |
PECs from C57BL/6 and B-cell-deficient mice harbor a high frequency
of
HV68-infected cells after i.p. inoculation.
To quantitate
the frequency of cells that reactivate
HV68, we have developed an ex
vivo limiting dilution reactivation assay (24). In this
assay, defined numbers of latently infected cells are plated on an
indicator layer of MEF cells (which replicates reactivated
HV68).
Viral CPE on the fibroblast monolayer is scored 2 to 3 weeks after
plating of the test cells. Since reactivation from latency requires
live cells, the presence of preformed infectious virus can be detected
by disrupting live cells without inactivating preformed infectious
virus (see below and reference 24). Using this
assay, we surveyed hematopoietic cell reservoirs for the presence of
latent
HV68 after i.p. inoculation of C57BL/6 and B-cell-deficient
mice. Resident PECs harbored a high frequency of cells that reactivate
HV68 in both C57BL/6 and B-cell-deficient (MuMT) mice 42 days
postinfection (Fig. 1). Indeed, the
frequency of PECs that reactivate
HV68 was ~50-fold higher than
the frequency of splenocytes that reactivate
HV68 (Fig. 1). Low
frequencies of cells that reactivate
HV68 were also detected in bone
marrow cells from both C57BL/6 and B-cell-deficient mice, while an even lower frequency was detected in thymocytes. The profiles of
HV68 reactivation from different hematopoietic cell reservoirs were very
similar in C57BL/6 and B-cell-deficient mice. However, the frequency of
cells which reactivated
HV68 was consistently ~100-fold higher in
cell populations from
HV68-infected B-cell-deficient mice than in
HV68-infected C57BL/6 mice.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Survey of HV68 latency in lymphoid organs from
B-cell-deficient mice (MuMT) and C57BL/6 mice 42 days postinfection.
Limiting dilution assay to detect reactivation from latency was
performed with cells from the spleen, bone marrow, thymus, or resident
PECs from B-cell-deficient or C57BL/6 mice. Shown are the percentages
of wells that scored positive for viral CPE 3 weeks after plating, as a
function of the number of cells plated per well; 24 wells were plated
per each cell dilution in each experiment. Shown in the bottom panels
are the results obtained when cells were killed by mechanical
disruption prior to plating, which indicates that no preformed
infectious virus was present in any of the samples tested.
B-cell-deficient mice demonstrated latent virus in the same organ
systems as C57BL/6 mice. The frequency of cells that reactivated latent
virus from B-cell-deficient mice was about 100-fold higher than from
C57BL/6 mice in all organs tested. Data represent averages of three to
seven separate experiments. Cells from three to five mice per group
were pooled and assayed per experiment. Error bars represent standard
errors from the means.
|
|
Notably, no evidence of preformed infectious virus was detected in the
PEC population, as determined by plating mechanically
disrupted cells
(Fig.
1). To ensure that the reactivation assay
was able to distinguish
between the presence of preformed infectious

HV68 and reactivation
from latency in the PEC population, we
determined the sensitivity of
the limiting dilution assay for
detection of preformed infectious
virus. A limiting dilution titration
of

HV68 was carried out before
and after mechanical disruption
in the presence and absence of PECs
(Fig.
2). Limiting dilution
analysis of
virus alone confirmed that this assay is ~5-fold more
sensitive than
the standard plaque assay (i.e., detects 0.2 PFU
of

HV68) [Fig.
2A
and reference
24]). Mechanical disruption
of virus
alone (Fig.
2B) or in the presence of PECs (Fig.
2C)
did not
significantly inhibit detection of preformed infectious
virus. Since we
detected 0.2 PFU/well, and since no preformed
infectious virus was
detected when 10
4 to 10
5 PECs or spleen cells
from latently infected organs were evaluated
after mechanical
disruption (Fig.
1), we concluded that there
is <1 PFU of

HV68 per
5 × 10
4 to 5 × 10
5 cells. The
frequency of cells reactivating

HV68 is much higher
than this (see
below), indicating that preformed infectious virus
cannot explain
results from the limiting dilution reactivation
assay. This finding
proved that we are detecting and quantitating
latent

HV68 using this
assay.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Detection of infectious virus is not affected by
mechanical disruption of PECs. Serial twofold dilutions of a stock of
HV68 virus, which had a known titer as determined by plaque assay on
NIH 3T12 fibroblasts, were plated on a monolayer of MEF cells in
96-well plates. The percentage of wells that scored positive for viral
CPE is shown as a function of log PFU (as determined by plaque assay)
plated per well. (A) Stock HV68 virus; (B) HV68 virus subjected
to a mechanical disruption process which kills >99% of cells (see
Materials and Methods); (C) HV68 virus inoculated into PECs from
C57BL/6 mice prior to mechanical disruption of cells. The vertical
lines indicate the log PFU per well in which 63.2% of the wells scored
positive. By Poisson distribution, 0.2 PFU could be detected with virus
alone, and between 0.2 and 0.4 PFU could be detected after mechanical
disruption alone or after mechanical disruption in the presence of
PECs. Data represent averages of five separate experiments. Error bars
represent standard errors from the means.
|
|
Clinical course of
HV68 infection in B-cell-deficient mice.
Intraperitoneal inoculation of C57BL/6 mice with 1 × 106 to 2 × 106 PFU of
HV68 does not
lead to significant morbidity or mortality over the course of 1 year
p.i. (reference 25 and data not shown). In contrast,
as we have previously reported, a significant percentage of
HV68-infected B-cell-deficient mice develop an arteritis that affects the great elastic vessels (25). In addition, as
shown here (e.g., Fig. 1) and previously (24),
B-cell-deficient mice harbor a significantly higher frequency of cells
that reactivate
HV68 than C57BL/6 mice. Given these abnormalities in
B-cell-deficient mice, we evaluated mortality of B-cell-deficient
compared to control mice over a prolonged period. Most
HV68-infected
B-cell-deficient mice (but not uninfected B-cell-deficient mice) died
between 100 and 250 days postinfection (Fig.
3). These data on mortality, combined
with the presence of arteritis and higher frequencies of cells that
reactivate
HV68 in B-cell-deficient mice, led us to perform a more
complete evaluation of chronic infection in B-cell-deficient and
C57BL/6 mice.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
B-cell-deficient mice (MuMT) eventually succumb after
infection with HV68. The Kaplan-Meier survival curve of
B-cell-deficient versus C57BL/6 mice after i.p. inoculation with
106 PFU of HV68 shows that 94% of B-cell-deficient mice
died 21 to 203 days p.i. The last two B-cell-deficient mice were
sacrificed 250 days p.i. None of the C57BL/6 mice died. Uninfected
(uninf) mouse controls were breeders sacrificed at 189 to 378 days of
age. Data are the pooled results of three separate experiments.
|
|
Establishment of
HV68 latency in C57BL/6 and B-cell-deficient
mice is not dependent on the route of inoculation.
Our previous
studies, demonstrating the establishment of
HV68 latency in
B-cell-deficient mice (24), apparently conflict with the
data of Usherwood et al. (21), who reported that
B-cell-deficient mice do not harbor splenic latent virus (although a
more recent analysis by these investigators has provided evidence of
latent infection in the lungs of B-cell-deficient mice
[16]). Two potentially significant differences between
the experimental system we have employed and that used by Usherwood et
al. (21) are (i) the route of inoculation and (ii) the assay
used to detect latent virus. While we have used the i.p. route of
inoculation, Usherwood et al. (21) infected mice by i.n.
inoculation. To determine whether route of inoculation affects the
establishment of latency in C57BL/6 and B-cell-deficient mice, we
compared the i.n. and i.p. routes of inoculation of C57BL/6 and
B-cell-deficient mice on days 9, 15, and 49 postinfection.
(i) Intraperitoneal inoculation leads to establishment of latency
in the spleen and peritoneum of both C57BL/6 and B-cell-deficient
mice.
After i.p. inoculation, C57BL/6 mice had preformed
infectious
HV68 in the spleen on day 9 postinfection (demonstrated
by the presence of viral CPE in wells receiving mechanically disrupted cells) (Fig. 4A). Preformed infectious
virus was cleared by day 15 postinfection (Fig. 4A; compare
mechanically disrupted cells on days 9 and 15). In contrast,
B-cell-deficient mice did not harbor infectious virus on day 9 or 15 postinfection (Fig. 4A). These results are consistent with our previous
results (24), and with immunohistochemical staining for
HV68 antigens with a polyclonal antiserum (4a),
demonstrating a critical role for B cells in the efficient
establishment of acute infection of the spleen 9 days postinfection.
Latent
HV68 was detected in PECs and splenocytes of both C57BL/6 and
B-cell-deficient mice after i.p. inoculation. The frequency of cells
reactivating
HV68 in PECs was higher than in the spleen at all times
tested (Fig. 4A). The frequency of cells reactivating
HV68 from both
PECs and splenocytes was higher from latently infected B-cell-deficient
mice than from latently infected C57BL/6 mice (Fig. 1 and 4A).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Establishment of latency in B-cell-deficient mice is not
dependent on the route of inoculation. HV68 latency was determined
after i.p. (A) and i.n. (B) inoculation. Mice were infected in parallel
with 106 PFU of HV68. Limiting dilution assay to detect
reactivation from latency was performed on PECs and splenocytes
isolated from B-cell-deficient (MuMT) and C57BL/6 mice 9 days, 15 days,
and 7 weeks postinfection. Shown is the percentage of wells that scored
positive for viral CPE as a function of the number of cells plated per
well, 3 weeks after plating; 24 wells were plated per cell dilution per
experiment. Shown in open symbols are the results obtained when cells
were killed by mechanical disruption prior to plating, representing
preformed infectious virus. Data represent averages of two separate
experiments. Three mice per group were assayed per experiment. Error
bars represent standard errors from the means.
|
|
(ii) Intranasal inoculation leads to establishment of latency in
the peritoneum and spleen of C57BL/6 mice and in the peritoneum, but
not the spleen, of B-cell-deficient mice.
Establishment of latency
in the spleen and peritoneum differed between mice infected by the i.n.
route and those infected i.p. (Fig. 4). No infectious virus was
detected on day 9 postinfection in the spleens of C57BL/6 mice after
i.n. inoculation (compare mechanically disrupted cells in Fig. 4). This
may be because the peak of viral infection appeared to be earlier after
i.n. inoculation than i.p. inoculation (18, 24) or because
systemic infection is less efficient after i.n. inoculation. Latent
virus was detected in C57BL/6 mouse spleens, but not in
B-cell-deficient mouse spleens, on day 15 after i.n. inoculation (Fig.
4B). Although 9 days postinfection, a low frequency of cells that
reactivate
HV68 was detected in both B-cell-deficient mouse and
C57BL/6 spleens, the detection of latently infected cells was just
above the limit of detection of the in vitro reactivation assay
(100,000 splenocytes per well), and latent virus was less consistently
observed in B-cell-deficient than C57BL/6 mice (note error bars). These
data are consistent with those of Usherwood et al. (21)
using a different assay to detect latent virus, in which it was found
that B-cell-deficient mice do not establish detectable
HV68 latency
in the spleen 7 to 35 days after i.n. inoculation.
Seven weeks after i.n. inoculation, PECs from both B-cell-deficient and
C57BL/6 mice harbored latent virus, although establishment
of latency
in PEC was delayed after i.n. compared with i.p. inoculation
(compare
Fig.
4A and B). Thus, establishment of latency in peritoneal
cells of
both C57BL/6 and B-cell-deficient mice is not dependent
on the route of
inoculation. This finding demonstrated that peritoneal
cells contain a
cell type (present in B-cell-deficient mice and
thus not a B cell) that
harbors latent

HV68 in
vivo.
Comparison of
HV68 reactivation as a function of time
postinfection in C57BL/6 and B-cell-deficient mice reveals that B cells
are important for controlling the frequency of cells reactivating
latent
HV68.
After i.n. inoculation, the frequency of cells
reactivating
HV68 detected in C57BL/6 spleens was lower at 7 weeks
postinfection than at 15 days postinfection (Fig. 4B). Similarly, after
i.p. inoculation, the frequency of cells that reactivated
HV68 from C57BL/6 PECs and spleen decreased over time (Fig. 4A). In contrast to
the results obtained for C57BL/6 mice, the frequency of cells from
B-cell-deficient mice that reactivated
HV68 from PECs and splenocytes did not decrease significantly over 7 weeks postinfection. To gain a more complete picture of the establishment of
HV68 latency
in C57BL/6 and B-cell-deficient mice, the kinetics of
HV68 latency
over 250 days of infection was determined by the ex vivo reactivation
assay (Fig. 5 and
6). In addition, recrudescent
HV68
infection has been observed in major histocompatibility complex class
II-deficient mice (3), and a sensitive assay for linear
HV68 genomes has detected lytic
HV68 replication in the lungs of
HV68-infected B-cell-deficient mice late after infection
(16). These data, coupled to the fact that
HV68-infected B-cell-deficient mice die over time (Fig. 3), provided a rationale for
determining whether preformed infectious
HV68 appeared in spleens
and PECs at late times after infection with
HV68.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Time course of latency in B-cell-deficient (MuMT) and
C57BL/6 mice, as detected by ex vivo reactivation assay. Limiting
dilution assay to detect reactivation from latency was performed at
various days postinfection from splenocytes and PECs of i.p.-inoculated
mice. Data from similar days were pooled. , C57 cells; , MuMT
cells; and , C57 and MuMT cells killed by mechanical disruption
prior to plating, representing preformed infectious virus. Data
represent averages of multiple separate experiments, as indicated (n).
Three mice per group were assayed per experiment. Error bars represent
standard errors from the means. Dotted lines indicate 63.2%, which was
used to calculate the frequency of reactivating cells by Poisson
distribution.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 6.
Estimation of the frequency of reactivating latently
infected cells at various times after infection. The frequency of
reactivating PECs or splenocytes from B-cell-deficient and C57BL/6 mice
was calculated at various times postinfection for each individual
experiment represented in Fig. 4. Reciprocal frequency indicates the
number of cells plated per well when 63.2% of the wells scored
positive for viral CPE (Poisson distribution). Symbols are as in Fig.
5. Infectious virus was cleared from PECs by day 9 postinfection in
both B-cell-deficient and C57BL/6 mice and was cleared from the spleen
by day 9 in B-cell-deficient mice and on day 11 in C57BL/6 mice. The
frequency of latent cells cannot be determined on days prior to
clearance of infectious virus. Each point represents at least one
experiment. For days postinfection on which more than one experiment
was performed, error bars represent standard errors from the means.
|
|
(i) Lack of preformed infectious
HV68 in the spleen and PECs of
B-cell-deficient mice at late times after infection.
We determined
whether detectable levels of preformed infectious virus were present in
splenocytes and PECs of B-cell-deficient and C57BL/6 mice between 9 and
250 days after infection. Infectious virus was detected in the PEC
population of both B-cell-deficient and C57BL/6 mice on day 5 postinfection but was cleared by day 9 postinfection, at which time
viral latency could readily be detected in the PEC population (Fig. 5
and 6). After this initial time point, preformed infectious virus was
detected very sporadically and at low levels (<1 PFU per 5 × 104 splenocytes or PECs) in both B-cell-deficient and
C57BL/6 mice (Fig. 5). There was no consistent increase in the
frequency of preformed infectious virus over time, and B-cell-deficient
and C57BL/6 mice did not differ significantly. We concluded that
recrudescent infection in spleen and PECs was not occurring in normal
or B-cell-deficient mice.
(ii) Frequencies of PECs and splenocytes that reactivate latent
HV68 are very similar in C57BL/6 and B-cell-deficient mice at early
times postinfection.
At days 9 and 10 postinfection, the frequency
of cells reactivating
HV68 could not be determined in splenocytes
harvested from C57BL/6 mice due to ongoing acute virus replication
(Fig. 5 and 6; note the presence of preformed infectious virus detected in the disrupted cell samples). However, by 13 to 15 days
postinfection, preformed infectious virus was cleared from the spleens
of C57BL/6 mice and the frequencies of cells reactivating
HV68 were
nearly identical in C57BL/6 and B-cell-deficient mice (Fig. 5 and 6). Similarly, at days 9 and 10 postinfection, the frequencies of PECs
reactivating
HV68 were very similar in C57BL/6 and B-cell-deficient mice. Thus, patterns of establishment of latency were very similar at
early times postinfection in C57BL/6 and B-cell-deficient mice, indicating that the absence of B cells does not grossly perturb this process.
(iii) The frequency of C57BL/6 PECs and splenocytes that reactivate
HV68 decreases dramatically over the first 4 weeks
postinfection.
In C57BL/6 mice, the frequency of cells
reactivating
HV68 decreased dramatically (about 500-fold in PECS and
>10-fold in splenocytes) between days 15 and 42 postinfection and
appeared to reach a low, steady-state level (Fig. 5 and 6). The
estimated frequency of cells reactivating
HV68 in C57BL/6 spleen was
about 1 in 10,000 cells on days 13 to 15 postinfection, which decreased to fewer than 1 in 100,000 cells (the limit of detection of the assay)
by day 30 postinfection. The estimated frequency of latent cells in
C57BL/6 PEC was about 1 in 100 cells on day 9 postinfection, which
decreased to about 1 in 1,000 cells on days 13 to 15 postinfection and
to about 1 in 50,000 cells at later times.
(iv) The frequency of B-cell-deficient mouse PECs and splenocytes
that reactivate
HV68 remains fairly constant, even at late times
postinfection.
The frequency of cells reactivating
HV68 from
B-cell-deficient mice at most time points was much higher than the
frequency observed in the equivalent cell populations harvested from
C57BL/6 mice. The frequency of cells reactivating
HV68 from
B-cell-deficient mice was relatively stable over time (Fig. 5 and 6).
Approximately 1 in 4,000 B-cell-deficient mouse splenocytes harvested
on day 9 postinfection reactivated virus, while ~1 in 10,000 B-cell-deficient mouse splenocytes reactivated virus by day 150 postinfection.
With PECs harvested from infected B-cell-deficient mice, the frequency
of reactivation from latency was significantly higher
than with
splenocytes. Approximately 1 in 100 PECs reactivated
virus on day 9 postinfection. The frequency of reactivation remained
between 1 in 100 to 1 in 1,000 cells through day 150 postinfection
(Fig.
6). However,
between days 150 and 250 postinfection there
was a substantial drop in
the observed frequency of reactivation
to ~1 in 10,000 cells
reactivating

HV68. As discussed above,
the majority of infected
B-cell-deficient mice died between days
100 and 200 postinfection (by
day 250 postinfection, 94% of infected
B-cell-deficient mice were dead
[Fig.
3]). Thus, B-cell-deficient
mice analyzed on days 150 and 250 postinfection represent a subset
of the animals originally infected.
Thus, analysis of infected
B-cell-deficient mice at late times
postinfection may select for
animals with the lowest levels of latent
virus.
Latently infected C57BL/6 and B-cell-deficient mice harbor similar
frequencies of
HV68 genome-positive cells.
Multiple mechanisms
might explain the persistence of high frequencies of cells reactivating
HV68 in B-cell-deficient mouse tissues over time. We elected to test
the hypothesis that the frequency of cells reactivating
HV68 is
directly related to the frequency of
HV68 genome-positive cells
present in tissues. We therefore determined the frequency of
HV68
genome-positive cells in PEC and splenocyte populations harvested from
latently infected C57BL/6 and B-cell-deficient mice at various times
postinfection (Fig. 7). The presence of
viral genome was assessed by using a nested PCR assay to detect the
presence of
HV68 gene 50 sequences in serial dilutions of cells from
latently infected mice (see Materials and Methods). This assay has been
shown to detect a single copy of the viral genome in a background of
cellular DNA from 104 cells (26). In parallel,
the frequency of cells that reactivate
HV68 in vitro was determined
by the limiting dilution reaction assay (see Materials and Methods).
Comparison of the frequency of genome-positive cells to the frequency
of cells reactivating
HV68 allowed us to measure the efficiency of
reactivation in different cell populations.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 7.
Comparison of the frequency of cells that harbor viral
genome to the frequency of cells that reactivate virus in vitro, after
i.p. inoculation. PECs (A) or splenocytes (B) from B-cell-deficient
(MuMT) or C57BL/6 mice were analyzed by two different methods in
parallel, at various times postinfection. Reactivation was quantitated
by limiting dilution reactivation assay. The results of reactivation
assay using disrupted cells, representing infectious virus, are shown
in open symbols. The frequency of genome-positive cells was determined
by dilutional nested PCR. Shown are the percentages of reactivation or
PCR assays that scored positive as a function of the number of cells
analyzed. For each cell number, 24 wells or 12 PCR assays were analyzed
per experiment. The dotted line indicates 63.2%, which was used to
calculate the frequency of reactivating or genome-positive cells by
Poisson distribution. Data represent single experiments, or the average
of multiple separate experiments, as indicated (n). Each experiment
represents a pool of three mice. Error bars represent standard errors
from the means.
|
|
(i) Correlation between viral genome load and frequency of
HV68
reactivation from B-cell-deficient mice and detection of organ-specific
differences in reactivation efficiency.
When PECs from latently
infected B-cell-deficient mice were analyzed, a very good correlation
between the frequency of cells that reactivated
HV68 and the number
of
HV68 genome-positive cells was observed over the time course from
days 9 to 250 postinfection (Fig. 7A). This finding indicated that
nearly all genome-positive PECs reactivated in the in vitro culture
system. When splenocytes from the infected B-cell-deficient mice were
analyzed, the frequency of
HV68 reactivation was consistently lower
than the frequency of
HV68-genome positive cells over the entire
time course (Fig. 7B). Notably, the frequency of splenocytes harboring
viral genome remained fairly constant (~1 in 400 cells) over this
time interval, while the frequency of reactivation dropped from ~1 in
5,000 to ~1 in 20,000 cells (Fig. 7B). Thus, unlike latently infected
PECs, it appears that only 2 to 10% of viral genome-positive
splenocytes isolated from B-cell-deficient mice reactivated latent
HV68 in the in vitro reactivation assay.
(ii) Correlation between viral genome load and frequency of
HV68
reactivation from C57BL/6 mice.
We expected the decreased
frequency of reactivation seen in PECs and splenocytes from C57BL/6
mice over time (Fig. 5 and 6) to be explained by decreased frequencies
of genome-positive cells. However, quantitation of the frequency of
genome-positive cells in C57BL/6 mice led to the surprising observation
that these animals harbor nearly as many
HV68 genome-positive cells
as do latently infected B-cell-deficient mice. Comparison of the
frequencies of
HV68 genome-positive PECs and ex vivo reactivation
revealed that the load of viral genome in C57BL/6 splenocytes and PECs remained very high over the time course examined, while the frequency of reactivation dropped dramatically (Fig. 5 to 7).
Notably, it was not possible to compare the frequencies of viral
genome-positive and reactivating splenocytes at day 9 after
infection
of C57BL/6 mice due to the presence of ongoing virus
replication in the
spleen at this time point (Fig.
7B, disrupted
cells). However, latency
was established in C57BL/6 PECs by day
9 postinfection, as preformed
infectious virus was not detected
(Fig.
7A, disrupted cells). At early
times postinfection (day
9), the frequency of genome-positive PECs and
the frequency of
reactivation correlated very closely for cells from
C57BL/6 and
B-cell-deficient mice (Fig.
7A). Thus, initial
establishment of
latency and initial efficiency of reactivation were
similar for
B-cell-deficient and C57BL/6
mice.
In marked contrast to results obtained 9 days afterinfection, by days
100 to 200 postinfection, in C57BL/6 mice the frequency
of

HV68
genome-positive PECs was ~1 in 200 cells whereas the
frequency of
reactivation was <1 in 10,000 cells (Fig.
7A). Similarly,
when
splenocytes from C57BL/6 mice were analyzed, the frequency
of viral
genome-positive cells (~1 in 500 to 2,000 cells) was
much greater at
days 42 and 127 postinfection than the frequency
of reactivating cells
(<1 in 100,000 cells) (Fig.
7B). Thus, at
late times after infection
significantly less than 1% of

HV68
genome-positive PECs or
splenocytes recovered from latently infected
C57BL/6 mice reactivated
in vitro. In contrast, in B-cell-deficient
mice, there was a much
closer correlation between the frequency
of

HV68 genome-positive
cells and reactivation frequency. In
both C57BL/6 and B-cell-deficient
mice, the efficiency of reactivation
from

HV68 genome-positive
splenocytes was lower than that from
genome-positive
PEC.
(iii) Relationship between genome load and
HV68 reactivation
after i.n. inoculation.
Since the frequency of reactivation from
PECs and splenocytes was very low by 7 weeks after i.n. inoculation of
C57BL/6 mice (Fig. 4B), we determined whether a disparity between the
frequency of viral genome harboring cells and reactivation also exists
after i.n. inoculation. Analysis of the viral genome load 7 weeks after i.n. inoculation revealed a large disparity between the frequency of
genome-positive splenocytes and the frequency of reactivation in
C57BL/6 mice, similar to that observed after i.p. inoculation (Fig.
8). Notably, the frequency of
genome-positive splenocytes after i.n. inoculation (ca. 1 in 3,000 cells) was very similar to the frequency observed after i.p.
inoculation (Fig. 7). As expected, when the frequency of viral
genome-positive splenocytes in B-cell-deficient mice 7 weeks after i.n.
inoculation was determined, very low frequencies of
HV68-positive
cells were detected (Fig. 8). The latter is consistent with the failure
to detect virus reactivation from the spleens of B-cell-deficient mice
after i.n. inoculation (Fig. 3B and reference 21).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 8.
Comparison of the frequency of genome-positive cells to
reactivation frequency ex vivo 7 weeks after i.n. inoculation. PECs and
splenocytes from B-cell-deficient and C57BL/6 mice were analyzed by two
different methods in parallel. Reactivation ( ) was quantitated by
limiting dilution reactivation assay. The frequency of genome-positive
cells was determined by dilutional nested PCR ( ). Shown are the
percentages of reactivation or PCR assays that scored positive as a
function of the number of cells analyzed. For each cell number, 24 wells or 12 PCR assays were analyzed per experiment. The dotted line
indicates 63.2%, which was used to calculate the frequency of
reactivating or genome-positive cells by Poisson distribution. Data
represent averages of two separate experiments. Three mice per group
were assayed per experiment. Error bars represent standard errors from
the means.
|
|
Examination of PECs isolated from B-cell-deficient mice 7 weeks
postinfection revealed both a relatively high frequency of
genome-positive cells (~1 in 2,000 cells) and a slightly lower
frequency of

HV68 reactivating cells (~1 in 10,000 cells).
However,
similar to the observations after i.p. inoculation, a much
greater
proportion of genome-positive PECs from B-cell-deficient mice
than from C57BL/6 mice reactivated in vitro. As after i.p. inoculation,
the frequency of viral genome-positive C57BL/6 PECs 7 weeks
postinfection
(~1 in 2,000 cells) was substantially higher than the
frequency
of C57BL/6 PECs reactivating

HV68 (<1 in 100,000 cells).
Thus,
very similar relationships between viral genome load and
reactivation
were observed after either i.p. or i.n.
inoculation.
(iv) Comparison of viral genome load in latently infected
B-cell-deficient and C57BL/6 mice 42 to 50 days postinfection reveals a
higher frequency of PECs harboring virus in B-cell-deficient mice than
in C57BL/6 mice.
Data compiled from several independent
experiments with cells harvested between days 42 and 50 after i.p.
inoculation revealed that there were ca. 6-fold more
HV68
genome-positive PECs in B-cell-deficient mice than in C57BL/6 mice
(Fig. 9). However, while a significant
difference was observed in the frequency of viral genome-positive PECs
in C57BL/6 and B-cell-deficient mice, no detectable difference was
observed in the frequency of viral genome-positive cells in the
splenocyte populations isolated from these strains of mice (Fig. 9).
Thus, the frequency of viral genome-positive PECs and splenocytes in
B-cell-deficient and C57BL/6 mice does not account for the large
difference in the frequency of cells reactivating
HV68 in these
mouse strains.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 9.
Comparison of the frequency of genome-positive cells
from C57BL/6 and B-cell-deficient mice 7 weeks after i.p. inoculation.
The frequency of genome-positive cells in PECs and splenocytes from
B-cell-deficient ( ) and C57BL/6 ( ) mice was determined by
dilutional nested PCR. Data shown are results from Fig. 5 plotted so as
to compare the frequency of genome-positive cells between
B-cell-deficient and C57BL/6 mice 7 weeks postinfection. The vertical
lines indicate the frequency of genome-positive cells for each
population, defined by the cell number that scored positive 63.2% of
the time (dotted lines). Data represent averages of multiple separate
experiments (n). Each experiment represents a pool of three mice. Error
bars represent standard errors from the means.
|
|
Mixing C57BL/6 and B-cell-deficient mouse latently infected PECs
does not significantly decrease the frequency of cells reactivating
HV68.
Since viral genome load does not explain the large
disparity in the frequency of cells from B-cell-deficient versus
C57BL/6 mice that reactivate
HV68, we considered the possibility
that a soluble factor (e.g., antibody) present in the C57BL/6
reactivation culture (and absent in the B-cell-deficient mouse
reactivation culture) is involved in blocking detection of reactivated
HV68. To address this possibility, we performed mixing experiments
in which PECs isolated from latently infected C57BL/6 mice were added to PECs isolated from latently infected B-cell-deficient mice in the
limiting dilution reactivation assay (Fig.
10). We chose to use PECs for this
analysis since (i) there was a very strong correlation between the
frequency of viral genome-positive cells and the frequency of cells
reactivating
HV68 in the PEC population isolated from
B-cell-deficient mice and (ii) the frequency of reactivation from PECs
was significantly higher than that from splenocytes, affording a more
accurate assessment of the relationship between cells isolated from
B-cell-deficient and C57BL/6 mice. We performed assays in which various
ratios of B-cell-deficient mouse and C57BL/6 PECs were mixed, along
with control assays in which B-cell-deficient mouse PECs or C57BL/6
PECs from latently infected mice were plated alone (Fig. 10). For this
analysis, PECs from infected mice were isolated either 41 (Fig. 10A) or
127 to 148 (Fig. 10B) days postinfection. It should be noted that for the analyses shown in Fig. 10, in which C57BL/6 and B-cell-deficient mouse cells were mixed, the number of B-cell-deficient mouse cells plated per well (as opposed to the total number of cells per well plated) was plotted, allowing a direct comparison of reactivation efficiency between the different groups.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 10.
Mixing latently infected C57BL/6 PECs and
B-cell-deficient (MuMT) PECs. Limiting dilution assay to detect
reactivation from latency was performed with PECs from B-cell-deficient
mice, C57BL/6 mice, or a mixture of the two at the ratios shown. Shown
are the percentages of wells that scored positive for viral CPE 3 weeks
after plating, as a function of the number of cells plated per well.
For assays containing both C57BL/6 and B-cell-deficient PECs, the
number of B-cell-deficient mouse PECs in each well was plotted versus
the percentage of wells positive for CPE; 24 wells were plated per each
cell dilution. PECs isolated 7 (A) and 18 to 21 (B) weeks postinfection
from three B-cell-deficient or C57BL/6 mice were pooled for each
experiment. Each panel represents a single experiment.
|
|
With PECs isolated from mice 41 days postinfection, a slight decrease
in the frequency of cells reactivating

HV68 was observed
at the
highest ratio of C57BL/6 PECs to B-cell-deficient mouse
PECs (Fig.
10A,
3:1 ratio). However, the frequency of C57BL/6 PECs
reactivating

HV68
was still 50- to 100-fold lower than the reactivation
frequency in
cultures containing a 3:1 ratio of C57BL/6 to B-cell-deficient
mouse
PECs (Fig.
10A). Similarly, when PECs isolated from C57BL/6
mice 127 days postinfection were mixed with PECs isolated from
B-cell-deficient
mice 148 days postinfection, no decrease in the
frequency of cells
reactivating

HV68 was observed (Fig.
10B).
These data argue against
the presence of a soluble factor generated
by C57BL/6 cells that
inhibits reactivation of

HV68 genome-positive
cells.
 |
DISCUSSION |
In this report we present a detailed analysis of
HV68 latency
in C57BL/6 and B-cell-deficient mice, test the hypothesis that the
frequency of genome-positive cells predicts the frequency of
gammaherpesvirus reactivation, and identify both organ-specific and
mouse strain-specific differences in the efficiency of
HV68 reactivation from latency. We demonstrate for the first time that regardless of route of inoculation, peritoneal cells are a rich source
of cells latently infected with
HV68 and that bone marrow is a
reservoir of cells harboring latent
HV68. Furthermore, our analysis
confirms that B cells are not required for the establishment of
HV68
latency in hematopoietic cells (24) but demonstrate a key
role of B cells in regulating
HV68 latency. In addition, it is now
clear that our initial observation of higher frequencies of cells
reactivating
HV68 in B-cell-deficient mice (24) largely reflects inefficient reactivation from C57BL/6 latently infected PEC
and splenocyte populations. It is possible that the observed differences in the behavior of
HV68 latently infected cells isolated from C57BL/6 and B-cell-deficient mice reflect a disregulation of
HV68 latency in vivo, contributing to a chronic and ultimately fatal
disease process in
HV68-infected B-cell-deficient mice.
Sites of
HV68 latency.
We found that resident PECs harbor a
high frequency of cells latently infected with
HV68 in both C57BL/6
and B-cell-deficient mice. In addition,
HV68 latency was observed in
the bone marrow. Studies here support our previous observation of
HV68 latency in B-cell-deficient mice (24) and provide
strong evidence that some hematopoeitic cell type other than a mature B
cell is a major reservoir for latent
HV68. It is interesting to
speculate that the latent cell types in the peritoneum and the bone
marrow are related and that the bone marrow may provide a source for
circulating cells that carry latent
HV68. Related to this, we have
identified macrophages (and, at a significantly lower level, B cells)
as the major cell type harboring latent
HV68 in PECs from C57BL/6 mice (26). As macrophages are bone marrow derived, further
experiments will need to address whether bone marrow-derived cells,
perhaps macrophages or B cells, contribute to
HV68 latency in other organs.
There is evidence that lung epithelial cells may also be a site of

HV68 latency (
16). However, the latter analysis did
not
unambiguously identify epithelial cells as a site of latent

HV68,
since it relied on the ability to detect by in situ hybridization
viral
tRNA-like transcripts (argued as a criterion for latency),
combined
with the failure to detect by in situ hybridization viral
transcripts
encoding glycoprotein H (gH) and thymidine kinase
(TK) (argued as
proving a lack of lytic replication). Because
the tRNAs are abundantly
expressed during the viral lytic cycle
(
2,
27), and the
relative sensitivities of in situ hybridization
for viral tRNA-like
transcripts versus gH and TK transcripts were
not determined, these
investigators may have simply detected tRNA-like
transcripts in
lytically infected epithelial cells that were not
expressing
sufficiently high levels of gH and TK transcripts to
be detected.
Indeed, linear viral genomes (diagnostic of ongoing
viral replication)
were detected in the lungs, but no gH/TK-positive
cells were detected
by in situ hybridization (
2). This finding
shows that in
situ hybridization was not sensitive enough to detect
lytic

HV68
replication even when the authors proved that such
cells must
exist.
Route of inoculation.
It has been supposed that i.n.
inoculation is the natural route of infection for
HV68. Based on
this argument, studies of
HV68 latency using i.p. inoculation have
been criticized as unphysiologic. However, experimental data
demonstrating respiratory spread of
HV68 have not been published. In
fact, the only published transmission of
HV68 occurred when an
uninfected dam ate infected pups (13). Thus, the natural
route of
HV68 infection is not known. Aside from possible enteral
infection, a sexual route of transmission, as well as transmission by
biting or scratching, may contribute to
HV68 spread in the natural
situation. Because the natural route of
HV68 has not been documented
experimentally, we compared latency by using two different routes, i.p.
and i.n. Regardless of route, the same organs examined carried latent
HV68. Of particular interest was the demonstration that peritoneal
cells are a rich source of cells carrying latent
HV68. We were
concerned that i.p. inoculation might contribute to the high frequency
of peritoneal cells carrying latent
HV68. However, the fact that
i.n. inoculation leads to latency in the peritoneum rules out the
trivial possibility that i.p. inoculation falsely accentuates the
significance of this reservoir. These data show that the route of
inoculation is not the primary determinant of sites of
HV68 latency.
The previously reported critical role for B cells in efficient
establishment of latency in the spleen (
21) after i.n.
inoculation
was confirmed by the studies presented here. This result
was previously
interpreted to indicate that B cells were the sole site
of latency
within the lymphoid compartment (
21). However,
the fact that
latency can be established in the spleen of
B-cell-deficient mice
after i.p. infection demonstrates that B cells
are not required
per se for generation of splenic latency. A role for B
cells in
trafficking

HV68 to the spleen has recently been
demonstrated
by Stewart et al. (
16). Adoptive transfer of
naive T-cell-depleted
splenocytes from C57BL/6 mice into
i.n.-inoculated latent B-cell-deficient
mice resulted in an increase in

HV68 genome-positive cells in
the spleens of the recipient
B-cell-deficient mice. These results
provide a likely explanation for
our finding splenic latency in
B-cell-deficient mice after i.p. but not
i.n. inoculation. B cells
likely play a key role in trafficking of
latent cells to the spleen
after i.n. inoculation, but this requirement
is likely overcome
by the more efficient establishment of systemic
infection that
occurs after i.p. inoculation. Notably, B cells were not
required
for establishment of latency in the peritoneum even after i.n.
inoculation. The latter suggests that distinct mechanisms are
involved
in trafficking virus to the spleen and
peritoneum.
Possible relationship between regulation of viral latency and
clinical course of
HV68 infection.
It is clear that the
clinical outcome of
HV68 infection in B-cell-deficient mice is very
different from that in C57BL/6 mice (>90% of B-cell-deficient mice
succumb to
HV68 infection between days 100 and 200 postinfection).
While the cause of death of the
HV68-infected B-cell-deficient mice
is unknown, the presence of a pronounced hemorrhagic exudative process
in the lungs of these mice was noted (data not shown), which raises the
possibility that they succumbed to a
HV68-associated pneumonia. This
possibility is supported by the demonstration of lytic
HV68
replication (as evidenced by the presence of linear genomes) in the
lungs of B-cell-deficient mice at late times after infection
(16). In addition, as discussed in results, ~70% of
HV68-infected B-cell-deficient mice have detectable arteritic
lesions at the base of the aorta, although these lesions are not
obstructive and may not contribute to mortality (25). We
have shown by electron microscopy that the arteritic lesions in
B-cell-deficient mice contain lytically replicating
HV68
(3a). The presence of lytic replication in two different organs (lungs and aorta) of B-cell-deficient mice late after infection could contribute to death of these animals. The relationship between the presence of continued viral replication in lung and aorta and high
frequencies of splenocytes and PECs that reactivate
HV68 in the ex
vivo assay is not known. However, it is interesting to speculate that
continued reactivation may seed the lung or aorta, contributing to
chronic pathology. It is also possible that continued replication of
HV68 at multiple sites alters the basic nature of
HV68 latency.
For example, latently infected cells from both C57BL/6 and
B-cell-deficient mice isolated early after infection reactivate
efficiently. In normal mice, the efficiency of reactivation decreases,
while the efficiency of reactivation is relatively stable in the
B-cell-deficient mice. One might argue that the efficiently
reactivating latent cells found in B-cell-deficient mice are actually
recently infected (seeded from lung or aorta). If there is a continuous
seeding of infectious virus into the latent reservoir in
B-cell-deficient mice, one might predict that the frequency of
genome-positive cells would be higher in B-cell-deficient mice than in
C57BL/6 mice. The only evidence consistent with this was that at 42 to
50 days postinfection, the frequency of
HV68 genome-positive cells
was ~6 fold higher in B-cell-deficient mice than in C57BL/6 mice. The
issue of how disregulation of latency and persistent production of
infectious virus relate will require further studies.
Relationship between viral genome-positive cells and viral
latency.
The availability of a small-animal model and quantitative
assays both for cells that reactivate
HV68 and for cells that carry
HV68 genome allowed us to analyze both the dynamics of establishment of latency in vivo and the efficiency of reactivation in an ex vivo assay.
(i) Organ-dependent differences in the efficiency of
HV68
reactivation.
By quantitating both the frequency of cells that
reactivate
HV68 and the frequency of cells that carry
HV68
genome, we were able to determine the parameters that regulate
HV68
latency. Two variables (organ and mouse strain) were important
determinants of the efficiency of reactivation of
HV68. Analysis of
PECs provided the clearest evidence that the majority of
HV68
genome-positive cells at this site are latently infected. In
B-cell-deficient mice, the frequency of cells reactivating
HV68 in
the PEC population correlated very closely with the frequency of
HV68 genome-positive cells. This close correlation was also true at
early times (e.g., day 9) in the PEC population isolated from infected
C57BL/6 mice. These data contrast with findings in splenocytes, which
were consistently less efficient at reactivating
HV68. Thus, fewer
genome-positive splenocytes reactivated in the ex vivo assay than
genome-positive PECs, regardless of mouse strain from which the cells
were isolated. This observation argues that either (i) a significant
proportion of splenocytes carrying the
HV68 genome are not latently
infected (i.e., they are unable to reactivate
HV68) or (ii) the
necessary stimulus for efficient reactivation of latently infected
splenocytes is not present in the ex vivo reactivation assay.
Differentiation of these two possibilities will require (i)
identification of the
HV68 latent gene program(s), (ii)
determination of whether cells in different organs express different
latent gene programs, and (iii) identification of specific signals that
induce
HV68 reactivation. In the case of
HV68 latent gene
expression, we have identified candidate viral genes that are expressed
in latently infected PEC and/or splenocytes (23). Notably,
distinct patterns of candidate latency-associated viral gene expression
were observed with RNA isolated from latently infected PECs versus
latently infected splenocytes, suggesting that there may indeed be
distinct
HV68 latency programs present in these two organ systems.
(ii) Mouse strain-dependent differences in the efficiency of
HV68 reactivation.
In addition to organ-specific effects on the
efficiency of reactivation, both PECs and splenocytes isolated from
B-cell-deficient mice reactivated
HV68 more efficiently than
comparable cell populations from C57BL/6 mice. This mouse
strain-dependent difference is not due to differences in background
genes, since we used B-cell-deficient mice backcrossed onto the C57BL/6
background and compared these mice to C57BL/6 mice. This finding
supports the hypothesis that the presence or absence of mature B cells
per se is a primary determinant of the nature of
HV68 latency. We
think it likely that this is in addition to a role for B cells in
trafficking
HV68, as outlined above. Either of two distinct
scenarios might explain differences in reactivation between C57BL/6 and
B-cell-deficient mice: (i) the presence of a B-cell-dependent (perhaps
immunologic) process in vivo results in a form of
HV68 latency from
which
HV68 does not efficiently reactivate ex vivo or (ii) the
presence of a B-cell-dependent process or mediator in the C57BL/6
reactivation culture regulates
HV68 reactivation (either by
inhibiting reactivation, or blocking detection of reactivated virus).
Since mixing cells from C57BL/6 mice with efficiently reactivating
cells from B-cell-deficient mice did not inhibit reactivation in the ex
vivo reactivation assay, we favor the former hypothesis.
In the presence of the complete immune system, B-cell-dependent
immunoselection may drive the appearance of a form of latency
from
which

HV68 reactivates inefficiently under the ex vivo culture
conditions. The latter hypothesis is based on the observed behavior
of
EBV in vivo, where it is now clear that there are multiple
latency
programs (
8,
14). In the case of EBV, it has been
shown that
viral gene expression, as well as the phenotype of
the long-term
latently infected B cell, is quite distinct from
that of the
EBV-immortalized lymphoblasts observed during the
acute phase of
infection (
14). The working hypothesis in the
case of EBV
infection is that immune surveillance detects and
destroys
EBV-immortalized B cells, which express an array of latency-associated
antigens involved in B-cell growth transformation, while the long-term
latency reservoir appears to express few (or no) viral antigens
and is
not detected by the host immune response. If the situation
for

HV68
is analogous, we may expect to find that genome-bearing
cells in
C57BL/6 mice express a different latency gene program
than similar
cells from B-cell-deficient mice. Analysis of this
hypothesis will
require (i) identification of cell types that
carry latent

HV68,
(ii) characterization of the anti-

HV68 immune
response in
B-cell-deficient mice, and (iii) definition of the
latency gene
program(s) used by this
gammaherpesvirus.
A number of different B-cell-dependent processes might influence the
nature of

HV68 latency. Since B cells are a site of
viral latency
(
19,
26) and are likely involved in trafficking

HV68,
presentation of latency-associated antigens by B cells
may be pivotal
to immune recognition of cells expressing certain
latent

HV68 genes.
Alternatively, the presence of immune antibody
may alter latency via
effects on intermittent reactivation and/or
dissemination of virus.
Evidence demonstrating a role for B cells
in regulating latent

HV68
comes from studies characterizing virus
replication in the lungs of

HV68-infected mice (
16). Depletion
of CD4 and CD8 T cells
from C57BL/6 mice did not lead to detectable
virus replication in the
lungs of these animals, but depletion
of CD4 and CD8 T cells from
infected B-cell-deficient mice resulted
in a dramatic increase in virus
titer in the lungs of these animals
(
16). The latter could
reflect a lack of antibody in B-cell-deficient
mice. This possibility
is supported by studies in the mouse cytomegalovirus
system
demonstrating a critical role for antibody in limiting
dissemination of
reactivated virus (
7).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology, Box 8118, 660 S. Euclid Ave., St. Louis, MO 63110. Phone for Herbert W. Virgin IV: (314) 362-9223. Phone for Samuel H. Speck: (314)
362-0367. Fax: (314) 362-4096. E-mail for Herbert W. Virgin IV:
virgin{at}pathology.wustl.edu. E-mail for Samuel H. Speck:
speck{at}pathology.wustl.edu.
 |
REFERENCES |
| 1.
|
Barkon, M. L.,
B. L. Haller, and H. W. Virgin, IV.
1996.
Circulating IgG can play a critical role in clearance of intestinal reovirus infection.
J. Virol.
70:1109-1116[Abstract].
|
| 2.
|
Bowden, R. J.,
J. P. Simas,
A. J. Davis, and S. Efstathiou.
1997.
Murine gammaherpesvirus 68 encodes tRNA-like sequences which are expressed during latency.
J. Gen. Virol.
78:1675-1687[Abstract].
|
| 3.
|
Cardin, R. D.,
J. W. Brooks,
S. R. Sarawar, and P. C. Doherty.
1996.
Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells.
J. Exp. Med.
184:863-871[Abstract/Free Full Text].
|
| 3a.
| Dal Canto, A. J., S. H. Speck, and H. W. Virgin IV. Unpublished data.
|
| 4.
|
Efstathiou, S.,
Y. M. Ho, and A. C. Minson.
1990.
Cloning and molecular characterization of the murine herpesvirus 68 genome.
J. Gen. Virol.
71:1355-1364[Abstract/Free Full Text].
|
| 4a.
| Gould, J. G., K. W. Weck, S. H. Speck,
and H. W. Virgin IV. Unpublished data.
|
| 5.
|
Heise, M. T.,
M. Connick, and H. W. Virgin.
1998.
Murine cytomegalovirus inhibits interferon-gamma induced antigen presentation to CD4 T cells by macrophages via regulation of MHC class II associated genes.
J. Exp. Med.
187:1037-1046[Abstract/Free Full Text].
|
| 6.
|
Heise, M. T., and H. W. Virgin, IV.
1995.
The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infection.
J. Virol.
69:904-909[Abstract].
|
| 7.
|
Jonjic, S.,
I. Pavic,
B. Polic,
I. Crnkovic,
P. Lucin, and U. H. Koszinowski.
1994.
Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus.
J. Exp. Med.
179:1713-1717[Abstract/Free Full Text].
|
| 8.
|
Kieff, E.
1996.
Epstein-Barr virus and its replication, p. 2343-2396.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven, Philadelphia, Pa.
|
| 9.
|
Kitamura, D.,
J. Roes,
R. Kuhn, and K. Rajewsky.
1991.
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.
Nature
350:423-426[Medline].
|
| 10.
|
Nash, A. A., and N. P. Sunil-Chandra.
1994.
Interactions of the murine gammaherpesvirus with the immune system.
Curr. Opin. Immunol.
6:560-563[Medline].
|
| 11.
|
Nash, A. A.,
E. J. Usherwood, and J. P. Stewart.
1996.
Immunological features of murine gammaherpesvirus infection.
Semin. Virol.
7:125-130.
|
| 12.
|
Pollock, J. L.,
R. M. Presti,
S. Paetzold, and H. W. Virgin.
1997.
Latent murine cytomegalovirus infection in macrophages.
Virology
227:168-179[Medline].
|
| 13.
|
Rajcani, J.,
D. Blaskovic,
J. Svobodova,
F. Ciampor,
D. Huckova, and D. Stanekova.
1985.
Pathogenesis of acute and persistent murine herpesvirus infection in mice.
Acta Virol.
29:51-60[Medline].
|
| 14.
|
Rickinson, A. B., and E. Kieff.
1996.
Epstein-Barr virus, p. 2397-2446.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lippincott-Raven, Philadelphia, Pa.
|
| 15.
|
Simas, J. P., and S. Efstathiou.
1998.
Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis.
Trends Microbiol.
6:276-282[Medline].
|
| 16.
|
Stewart, J. P.,
E. J. Usherwood,
A. Ross,
H. Dyson, and T. Nash.
1998.
Lung epithelial cells are a major site of murine gammaherpesvirus persistence.
J. Exp. Med.
187:1941-1951[Abstract/Free Full Text].
|
| 17.
|
Sunil-Chandra, N. P.,
J. Arno,
J. Fazakerley, and A. A. Nash.
1994.
Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68.
Am. J. Pathol.
145:818-826[Abstract].
|
| 18.
|
Sunil-Chandra, N. P.,
S. Efstathiou,
J. Arno, and A. A. Nash.
1992.
Virological and pathological features of mice infected with murine gammaherpesvirus 68.
J. Gen. Virol.
73:2347-2356[Abstract/Free Full Text].
|
| 19.
|
Sunil-Chandra, N. P.,
S. Efstathiou, and A. A. Nash.
1992.
Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo.
J. Gen. Virol.
73:3275-3279[Abstract/Free Full Text].
|
| 20.
|
Usherwood, E. J.,
A. J. Ross,
D. J. Allen, and A. A. Nash.
1996.
Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells.
J. Gen. Virol.
77:627-630[Abstract/Free Full Text].
|
| 21.
|
Usherwood, E. J.,
J. P. Stewart,
K. Robertson,
D. J. Allen, and A. A. Nash.
1996.
Absence of splenic latency in murine gammaherpesvirus 68-infected B cell-deficient mice.
J. Gen. Virol.
77:2819-2825[Abstract/Free Full Text].
|
| 22.
|
Virgin, H. W., IV,
P. Latreille,
P. Wamsley,
K. Hallsworth,
K. E. Weck,
A. J. Dal Canto, and S. H. Speck.
1997.
Complete sequence and genomic analysis of murine gammaherpesvirus 68.
J. Virol.
71:5894-5904[Abstract].
|
| 23.
|
Virgin, H. W., IV,
R. M. Presti,
X.-Y. Li,
C. Liu, and S. H. Speck.
1999.
Three distinct regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently infected mice.
J. Virol.
73:2321-2332[Abstract/Free Full Text].
|
| 24.
|
Weck, K. E.,
M. L. Barkon,
L. I. Yoo,
S. H. Speck, and H. W. Virgin, IV.
1996.
Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68.
J. Virol.
70:6775-6780[Abstract/Free Full Text].
|
| 25.
|
Weck, K. E.,
A. J. Dal Canto,
J. D. Gould,
A. K. O'Guin,
K. A. Roth,
J. E. Saffitz,
S. H. Speck, and H. W. Virgin.
1997.
Murine gamma-herpesvirus 68 causes large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease.
Nat. Med.
3:1346-1353[Medline].
|
| 26.
|
Weck, K. E.,
S. S. Kim,
H. W. Virgin IV, and S. H. Speck.
1999.
Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells.
J. Virol.
73:3273-3283[Abstract/Free Full Text].
|
| 27.
| Weck, K. E., H. W. Virgin IV, and S. H. Speck. Unpublished data.
|
Journal of Virology, June 1999, p. 4651-4661, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gredmark-Russ, S., Isaacson, M. K., Kattenhorn, L., Cheung, E. J., Watson, N., Ploegh, H. L.
(2009). A Gammaherpesvirus Ubiquitin-Specific Protease Is Involved in the Establishment of Murine Gammaherpesvirus 68 Infection. J. Virol.
83: 10644-10652
[Abstract]
[Full Text]
-
Collins, C. M., Boss, J. M., Speck, S. H.
(2009). Identification of Infected B-Cell Populations by Using a Recombinant Murine Gammaherpesvirus 68 Expressing a Fluorescent Protein. J. Virol.
83: 6484-6493
[Abstract]
[Full Text]
-
Krug, L. T., Collins, C. M., Gargano, L. M., Speck, S. H.
(2009). NF-{kappa}B p50 Plays Distinct Roles in the Establishment and Control of Murine Gammaherpesvirus 68 Latency. J. Virol.
83: 4732-4748
[Abstract]
[Full Text]
-
Gargano, L. M., Forrest, J. C., Speck, S. H.
(2009). Signaling through Toll-Like Receptors Induces Murine Gammaherpesvirus 68 Reactivation In Vivo. J. Virol.
83: 1474-1482
[Abstract]
[Full Text]
-
Gredmark-Russ, S., Cheung, E. J., Isaacson, M. K., Ploegh, H. L., Grotenbreg, G. M.
(2008). The CD8 T-Cell Response against Murine Gammaherpesvirus 68 Is Directed toward a Broad Repertoire of Epitopes from both Early and Late Antigens. J. Virol.
82: 12205-12212
[Abstract]
[Full Text]
-
DeZalia, M., Speck, S. H.
(2008). Identification of Closely Spaced but Distinct Transcription Initiation Sites for the Murine Gammaherpesvirus 68 Latency-Associated M2 Gene. J. Virol.
82: 7411-7421
[Abstract]
[Full Text]
-
Gargano, L. M., Moser, J. M., Speck, S. H.
(2008). Role for MyD88 Signaling in Murine Gammaherpesvirus 68 Latency. J. Virol.
82: 3853-3863
[Abstract]
[Full Text]
-
Herskowitz, J. H., Siegel, A. M., Jacoby, M. A., Speck, S. H.
(2008). Systematic Mutagenesis of the Murine Gammaherpesvirus 68 M2 Protein Identifies Domains Important for Chronic Infection. J. Virol.
82: 3295-3310
[Abstract]
[Full Text]
-
Evans, A. G., Moser, J. M., Krug, L. T., Pozharskaya, V., Mora, A. L., Speck, S. H.
(2008). A gammaherpesvirus-secreted activator of V{beta}4+ CD8+ T cells regulates chronic infection and immunopathology. JEM
205: 669-684
[Abstract]
[Full Text]
-
Steed, A., Buch, T., Waisman, A., Virgin, H. W. IV
(2007). Gamma Interferon Blocks Gammaherpesvirus Reactivation from Latency in a Cell Type-Specific Manner. J. Virol.
81: 6134-6140
[Abstract]
[Full Text]
-
Kim, I.-J., Burkum, C. E., Cookenham, T., Schwartzberg, P. L., Woodland, D. L., Blackman, M. A.
(2007). Perturbation of B Cell Activation in SLAM-Associated Protein-Deficient Mice Is Associated with Changes in Gammaherpesvirus Latency Reservoirs. J. Immunol.
178: 1692-1701
[Abstract]
[Full Text]
-
Upton, J. W., Speck, S. H.
(2006). Evidence for CDK-Dependent and CDK-Independent Functions of the Murine Gammaherpesvirus 68 v-Cyclin. J. Virol.
80: 11946-11959
[Abstract]
[Full Text]
-
Martin, A. P., Canasto-Chibuque, C., Shang, L., Rollins, B. J., Lira, S. A.
(2006). The Chemokine Decoy Receptor M3 Blocks CC Chemokine Ligand 2 and CXC Chemokine Ligand 13 Function In Vivo. J. Immunol.
177: 7296-7302
[Abstract]
[Full Text]
-
Allen, R. D. III, Dickerson, S., Speck, S. H.
(2006). Identification of Spliced Gammaherpesvirus 68 LANA and v-Cyclin Transcripts and Analysis of Their Expression In Vivo during Latent Infection. J. Virol.
80: 2055-2062
[Abstract]
[Full Text]
-
Moser, J. M., Farrell, M. L., Krug, L. T., Upton, J. W., Speck, S. H.
(2006). A Gammaherpesvirus 68 Gene 50 Null Mutant Establishes Long-Term Latency in the Lung but Fails To Vaccinate against a Wild-Type Virus Challenge. J. Virol.
80: 1592-1598
[Abstract]
[Full Text]
-
Steed, A. L., Barton, E. S., Tibbetts, S. A., Popkin, D. L., Lutzke, M. L., Rochford, R., Virgin, H. W. IV
(2006). Gamma Interferon Blocks Gammaherpesvirus Reactivation from Latency. J. Virol.
80: 192-200
[Abstract]
[Full Text]
-
Tarakanova, V. L., Suarez, F., Tibbetts, S. A., Jacoby, M. A., Weck, K. E., Hess, J. L., Speck, S. H., Virgin, H. W. IV
(2005). Murine Gammaherpesvirus 68 Infection Is Associated with Lymphoproliferative Disease and Lymphoma in BALB {beta}2 Microglobulin-Deficient Mice. J. Virol.
79: 14668-14679
[Abstract]
[Full Text]
-
Barton, E. S., Lutzke, M. L., Rochford, R., Virgin, H. W. IV
(2005). Alpha/Beta Interferons Regulate Murine Gammaherpesvirus Latent Gene Expression and Reactivation from Latency. J. Virol.
79: 14149-14160
[Abstract]
[Full Text]
-
Chen, G., Tai, A. K., Lin, M., Chang, F., Terhorst, C., Huber, B. T.
(2005). Signaling Lymphocyte Activation Molecule-Associated Protein Is a Negative Regulator of the CD8 T Cell Response in Mice. J. Immunol.
175: 2212-2218
[Abstract]
[Full Text]
-
Moser, J. M., Upton, J. W., Allen, R. D. III, Wilson, C. B., Speck, S. H.
(2005). Role of B-Cell Proliferation in the Establishment of Gammaherpesvirus Latency. J. Virol.
79: 9480-9491
[Abstract]
[Full Text]
-
Moser, J. M., Upton, J. W., Gray, K. S., Speck, S. H.
(2005). Ex Vivo Stimulation of B Cells Latently Infected with Gammaherpesvirus 68 Triggers Reactivation from Latency. J. Virol.
79: 5227-5231
[Abstract]
[Full Text]
-
Willer, D. O., Speck, S. H.
(2005). Establishment and Maintenance of Long-Term Murine Gammaherpesvirus 68 Latency in B Cells in the Absence of CD40. J. Virol.
79: 2891-2899
[Abstract]
[Full Text]
-
Herskowitz, J., Jacoby, M. A., Speck, S. H.
(2005). The Murine Gammaherpesvirus 68 M2 Gene Is Required for Efficient Reactivation from Latently Infected B Cells. J. Virol.
79: 2261-2273
[Abstract]
[Full Text]
-
Braaten, D. C., Sparks-Thissen, R. L., Kreher, S., Speck, S. H., Virgin, H. W. IV
(2005). An Optimized CD8+ T-Cell Response Controls Productive and Latent Gammaherpesvirus Infection. J. Virol.
79: 2573-2583
[Abstract]
[Full Text]
-
Liang, X., Shin, Y. C., Means, R. E., Jung, J. U.
(2004). Inhibition of Interferon-Mediated Antiviral Activity by Murine Gammaherpesvirus 68 Latency-Associated M2 Protein. J. Virol.
78: 12416-12427
[Abstract]
[Full Text]
-
Loh, J., Thomas, D. A., Revell, P. A., Ley, T. J., Virgin, H. W. IV
(2004). Granzymes and Caspase 3 Play Important Roles in Control of Gammaherpesvirus Latency. J. Virol.
78: 12519-12528
[Abstract]
[Full Text]
-
Martro, E., Cannon, M. J., Dollard, S. C., Spira, T. J., Laney, A. S., Ou, C.-Y., Pellett, P. E.
(2004). Evidence for both Lytic Replication and Tightly Regulated Human Herpesvirus 8 Latency in Circulating Mononuclear Cells, with Virus Loads Frequently below Common Thresholds of Detection. J. Virol.
78: 11707-11714
[Abstract]
[Full Text]
-
Yarilin, D. A., Valiando, J., Posnett, D. N.
(2004). A Mouse Herpesvirus Induces Relapse of Experimental Autoimmune Arthritis by Infection of the Inflammatory Target Tissue. J. Immunol.
173: 5238-5246
[Abstract]
[Full Text]
-
Sparks-Thissen, R. L., Braaten, D. C., Kreher, S., Speck, S. H., Virgin, H. W. IV
(2004). An Optimized CD4 T-Cell Response Can Control Productive and Latent Gammaherpesvirus Infection. J. Virol.
78: 6827-6835
[Abstract]
[Full Text]
-
McClellan, J. S., Tibbetts, S. A., Gangappa, S., Brett, K. A., Virgin, H. W. IV
(2004). Critical Role of CD4 T Cells in an Antibody-Independent Mechanism of Vaccination against Gammaherpesvirus Latency. J. Virol.
78: 6836-6845
[Abstract]
[Full Text]
-
Andreansky, S., Liu, H., Adler, H., Koszinowski, U. H., Efstathiou, S., Doherty, P. C.
(2004). The limits of protection by "memory" T cells in Ig-/- mice persistently infected with a {gamma}-herpesvirus. Proc. Natl. Acad. Sci. USA
101: 2017-2022
[Abstract]
[Full Text]
-
Townsley, A. C., Dutia, B. M., Nash, A. A.
(2004). The M4 Gene of Murine Gammaherpesvirus Modulates Productive and Latent Infection In Vivo. J. Virol.
78: 758-767
[Abstract]
[Full Text]
-
Fowler, P., Marques, S., Simas, J. P., Efstathiou, S.
(2003). ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. J. Gen. Virol.
84: 3405-3416
[Abstract]
[Full Text]
-
Moorman, N. J., Willer, D. O., Speck, S. H.
(2003). The Gammaherpesvirus 68 Latency-Associated Nuclear Antigen Homolog Is Critical for the Establishment of Splenic Latency. J. Virol.
77: 10295-10303
[Abstract]
[Full Text]
-
Mpandi, M., Otten, L. A., Lavanchy, C., Acha-Orbea, H., Finke, D.
(2003). Passive Immunization with Neutralizing Antibodies Interrupts the Mouse Mammary Tumor Virus Life Cycle. J. Virol.
77: 9369-9377
[Abstract]
[Full Text]
-
Willer, D. O., Speck, S. H.
(2003). Long-Term Latent Murine Gammaherpesvirus 68 Infection Is Preferentially Found within the Surface Immunoglobulin D-Negative Subset of Splenic B Cells In Vivo. J. Virol.
77: 8310-8321
[Abstract]
[Full Text]
-
Kim, I.-J., Flano, E., Woodland, D. L., Lund, F. E., Randall, T. D., Blackman, M. A.
(2003). Maintenance of Long Term {gamma}-Herpesvirus B Cell Latency Is Dependent on CD40-Mediated Development of Memory B Cells. J. Immunol.
171: 886-892
[Abstract]
[Full Text]
-
Marques, S., Efstathiou, S., Smith, K. G., Haury, M., Simas, J. P.
(2003). Selective Gene Expression of Latent Murine Gammaherpesvirus 68 in B Lymphocytes. J. Virol.
77: 7308-7318
[Abstract]
[Full Text]
-
Tibbetts, S. A., Loh, J., van Berkel, V., McClellan, J. S., Jacoby, M. A., Kapadia, S. B., Speck, S. H., Virgin, H. W. IV
(2003). Establishment and Maintenance of Gammaherpesvirus Latency Are Independent of Infective Dose and Route of Infection. J. Virol.
77: 7696-7701
[Abstract]
[Full Text]
-
Pavlova, I. V., Virgin, H. W. IV, Speck, S. H.
(2003). Disruption of Gammaherpesvirus 68 Gene 50 Demonstrates that Rta Is Essential for Virus Replication. J. Virol.
77: 5731-5739
[Abstract]
[Full Text]
-
van Dyk, L. F., Virgin, H. W. IV, Speck, S. H.
(2003). Maintenance of Gammaherpesvirus Latency Requires Viral Cyclin in the Absence of B Lymphocytes. J. Virol.
77: 5118-5126
[Abstract]
[Full Text]
-
Flano, E., Kim, I.-J., Moore, J., Woodland, D. L., Blackman, M. A.
(2003). Differential {gamma}-Herpesvirus Distribution in Distinct Anatomical Locations and Cell Subsets During Persistent Infection in Mice. J. Immunol.
170: 3828-3834
[Abstract]
[Full Text]
-
Tibbetts, S. A., McClellan, J. S., Gangappa, S., Speck, S. H., Virgin, H. W. IV
(2003). Effective Vaccination against Long-Term Gammaherpesvirus Latency. J. Virol.
77: 2522-2529
[Abstract]
[Full Text]
-
Flano, E., Kim, I.-J., Woodland, D. L., Blackman, M. A.
(2002). {gamma}-Herpesvirus Latency Is Preferentially Maintained in Splenic Germinal Center and Memory B Cells. JEM
196: 1363-1372
[Abstract]
[Full Text]
-
Gangappa, S., Kapadia, S. B., Speck, S. H., Virgin, H. W. IV
(2002). Antibody to a Lytic Cycle Viral Protein Decreases Gammaherpesvirus Latency in B-Cell-Deficient Mice. J. Virol.
76: 11460-11468
[Abstract]
[Full Text]
-
Tibbetts, S. A., van Dyk, L. F., Speck, S. H., Virgin, H. W. IV
(2002). Immune Control of the Number and Reactivation Phenotype of Cells Latently Infected with a Gammaherpesvirus. J. Virol.
76: 7125-7132
[Abstract]
[Full Text]
-
Clambey, E. T., Virgin, H. W. IV, Speck, S. H.
(2002). Characterization of a Spontaneous 9.5-Kilobase-Deletion Mutant of Murine Gammaherpesvirus 68 Reveals Tissue-Specific Genetic Requirements for Latency. J. Virol.
76: 6532-6544
[Abstract]
[Full Text]
-
Kim, I.-J., Flano, E., Woodland, D. L., Blackman, M. A.
(2002). Antibody-Mediated Control of Persistent {gamma}-Herpesvirus Infection. J. Immunol.
168: 3958-3964
[Abstract]
[Full Text]
-
Liu, H., Andreansky, S., Diaz, G., Hogg, T., Doherty, P. C.
(2002). Reduced Functional Capacity of CD8+ T Cells Expanded by Post-Exposure Vaccination of {gamma}-Herpesvirus-Infected CD4-Deficient Mice. J. Immunol.
168: 3477-3483
[Abstract]
[Full Text]
-
Jacoby, M. A., Virgin, H. W. IV, Speck, S. H.
(2002). Disruption of the M2 Gene of Murine Gammaherpesvirus 68 Alters Splenic Latency following Intranasal, but Not Intraperitoneal, Inoculation. J. Virol.
76: 1790-1801
[Abstract]
[Full Text]
-
Sanna, P. P., Burton, D. R.
(2000). Role of Antibodies in Controlling Viral Disease: Lessons from Experiments of Nature and Gene Knockouts. J. Virol.
74: 9813-9817
[Full Text]
-
Usherwood, E. J., Roy, D. J., Ward, K., Surman, S. L., Dutia, B. M., Blackman, M. A., Stewart, J. P., Woodland, D. L.
(2000). Control of Gammaherpesvirus Latency by Latent Antigen-Specific Cd8+ T Cells. JEM
192: 943-952
[Abstract]
[Full Text]
-
van Dyk, L. F., Virgin, H. W. IV, Speck, S. H.
(2000). The Murine Gammaherpesvirus 68 v-Cyclin Is a Critical Regulator of Reactivation from Latency. J. Virol.
74: 7451-7461
[Abstract]
[Full Text]
-
van Berkel, V., Barrett, J., Tiffany, H. L., Fremont, D. H., Murphy, P. M., McFadden, G., Speck, S. H., Virgin, H. W. IV
(2000). Identification of a Gammaherpesvirus Selective Chemokine Binding Protein That Inhibits Chemokine Action. J. Virol.
74: 6741-6747
[Abstract]
[Full Text]
-
Hoge, A. T., Hendrickson, S. B., Burns, W. H.
(2000). Murine Gammaherpesvirus 68 Cyclin D Homologue Is Required for Efficient Reactivation from Latency. J. Virol.
74: 7016-7023
[Abstract]
[Full Text]
-
Flano, E., Husain, S. M., Sample, J. T., Woodland, D. L., Blackman, M. A.
(2000). Latent Murine {gamma}-Herpesvirus Infection Is Established in Activated B Cells, Dendritic Cells, and Macrophages. J. Immunol.
165: 1074-1081
[Abstract]
[Full Text]
-
Clambey, E. T., Virgin, H. W. IV, Speck, S. H.
(2000). Disruption of the Murine Gammaherpesvirus 68 M1 Open Reading Frame Leads to Enhanced Reactivation from Latency. J. Virol.
74: 1973-1984
[Abstract]
[Full Text]
-
Parry, C. M., Simas, J. P., Smith, V. P., Stewart, C. A., Minson, A. C., Efstathiou, S., Alcami, A.
(2000). A Broad Spectrum Secreted Chemokine Binding Protein Encoded by a Herpesvirus. JEM
191: 573-578
[Abstract]
[Full Text]
-
Flano, E., Woodland, D. L., Blackman, M. A.
(1999). Requirement for CD4+ T Cells in V{beta}4+CD8+ T Cell Activation Associated with Latent Murine Gammaherpesvirus Infection. J. Immunol.
163: 3403-3408
[Abstract]
[Full Text]
-
Kapadia, S. B., Molina, H., van Berkel, V., Speck, S. H., Virgin, H. W. IV
(1999). Murine Gammaherpesvirus 68 Encodes a Functional Regulator of Complement Activation. J. Virol.
73: 7658-7670
[Abstract]
[Full Text]
-
Stevenson, P. G., Belz, G. T., Castrucci, M. R., Altman, J. D., Doherty, P. C.
(1999). A gamma -herpesvirus sneaks through a CD8+ T cell response primed to a lytic-phase epitope. Proc. Natl. Acad. Sci. USA
96: 9281-9286
[Abstract]
[Full Text]
-
Gangappa, S., van Dyk, L. F., Jewett, T. J., Speck, S. H., Virgin, H. W. IV
(2002). Identification of the In Vivo Role of a Viral bcl-2. JEM
195: 931-940
[Abstract]
[Full Text]